AstraZeneca (LSE: AZN) has reported positive findings from its Phase III MATTERHORN trial, spotlighting the potential of its ...

Arcus Biosciences (NYSE: RCUS) is setting the stage for a high-stakes Phase III showdown in kidney cancer, after early ...

A clinical-stage biotech company developing oral therapies for movement disorders, with an initial focus on dystonia.

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE: AZN) have released detailed Phase III results that could help position their ...

French pharma major Sanofi (Euronext: SAN) today revealed an agreement to acquire, and Blueprint Medicines (Nasdaq: BPMC), a US company, specializing in systemic mastocytosis (SM), a rare ...

Swiss generic and biosimilar medicines company Sandoz (SWX: SDZ) today announced that Wyost (denosumab) and Jubbonti ...

US drugmaker Protagonist Therapeutics (Nasdaq: PTGX) and Japan’s Takeda Pharma (TYO:4502) announced detailed results from the ...

Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial ...

The data showed a surprisingly compelling overall survival (OS) benefit. TheBraftovi combination regimen received Food and ...

In a website posting, the International Generic and Biosimilar medicines Association (IGBA) has commended the General ...

The development of new drugs is more expensive than ever. Last year, it cost an average of over $2.23 billion to develop one new drug.

Treating greater numbers of Danish patients with rare diseases requires a more open and shared dialogue about handling ...